Prostate Cancer Imaging Program Received FDA Fast Track
A new diagnostic approach could help you and your doctor avoid unnecessary prostate biopsies.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Would you prefer non-invasive imaging over a standard biopsy for initial cancer screening?
The FDA has granted Fast Track designation to Telix Pharmaceuticals’ BiPASS program, which aims to improve the accuracy of prostate cancer diagnosis. This regulatory status may speed up the review process for the imaging technology.
Why it matters
Up to 75% of the three million prostate biopsies performed annually yield negative results, suggesting a significant need for better diagnostic precision. This program seeks to reduce these invasive procedures by incorporating advanced imaging before a biopsy is performed.
Clinical data indicates that combining gallium-68 PSMA-PET imaging with MRI can reduce unnecessary prostate biopsies by nearly 50%. These findings were observed in the BiPASS program, for which patient enrollment has been completed.
The players
Telix Pharmaceuticals
An Australian-based biopharmaceutical company focused on developing diagnostic and therapeutic imaging products for cancer care.
FDA
The United States federal agency responsible for overseeing the safety and efficacy of medical devices and pharmaceuticals.
The details
The BiPASS program works by integrating gallium-68 PSMA-PET imaging with MRI to create a more detailed diagnostic map before a biopsy is considered. This combined approach allows clinicians to better visualize prostate tissue, potentially identifying cases that do not require invasive sampling. The FDA's Fast Track designation facilitates more frequent interaction between the manufacturer and regulators, which can expedite the development and review of new diagnostic tools.
Timeline
The FDA granted Fast Track designation to the BiPASS program in September 2026.
Telix Pharmaceuticals saw an 11% share price increase over the past 12 months.
Health Landscape
The BiPASS program represents an effort to integrate advanced PET and MRI imaging earlier into the prostate diagnostic workflow. This shift reflects a broader trend in oncology aimed at reducing the reliance on invasive biopsies through improved non-invasive imaging technologies.
If you are concerned about prostate health, this development highlights the potential of combining MRI and PSMA-PET imaging to provide more clarity before deciding on a biopsy. It is worth discussing with your doctor whether advanced imaging options are appropriate for your specific diagnostic needs.
The takeaway
Advanced imaging combinations may eventually reduce the frequency of unnecessary prostate biopsies by providing clearer pre-biopsy information. Ask your urologist about the current role of PSMA-PET and MRI in your diagnostic care plan.
Further reading
For more information on diagnostic innovations in oncology, visit our Cancer section.
Source note: This article includes information reported by Motley Fool Australia.
Live Poll
Would you prefer non-invasive imaging over a standard biopsy for initial cancer screening?
